about
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: A contemporary evaluation.Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma.Heavy Testosterone Use Among Bodybuilders: An Uncommon Cohort of Illicit Substance Users.Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy.Three-dimensional Printing for Renal Cancer and Surgical Planning.Ventral Slit Scrotal Flap: A New Outpatient Surgical Option for Reconstruction of Adult Buried Penis Syndrome.Ureteroarterial Fistulas After Robotic and Open Radical CystectomyAre We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?Media reporting of ProtecT: a disconnect in information dissemination?The Effect of Anticoagulation on Bleeding-related Complications Following Ureteroscopy.Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.Ectopic Penile Prosthesis Reservoir Placement: An Anatomic Cadaver Model of the High Submuscular Technique.Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes.Medication patterns and fertility rates in a cohort of anabolic steroid users.Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie DiseaseImpact of anabolic androgenic steroids on sexual functionTreatment of non-obstructive, non-struvite urolithiasis is effective in treatment of recurrent urinary tract infectionsIntercourse frequency among men presenting to a sexual health clinic: does age matter?
P50
Q36086878-9EC24247-A73A-4153-8453-27E14264E232Q37426988-F32C440F-A574-457F-AB1A-564C7D502E85Q38809408-C2E1A4E6-490B-4ED8-82CA-051F2CDAFED1Q40106406-A2C6C287-6E4E-4757-B912-B6EB12FE1B82Q40220251-C2031217-07C4-4FBB-84F2-E9ED24D843F6Q40487843-05061772-7897-42D7-9D82-5CFFB69B8A30Q41074864-FA4A0FD5-D087-4F0F-B8D6-19C16C818B05Q41253604-9152817C-DE4F-4482-A13C-ECA20263AECAQ47220533-9922A173-BB35-4F8F-ADC2-1D5BA62DFC57Q47888856-360D7285-2D24-4F32-BAD0-7F1F9DBAC897Q48778097-C19B7C96-02CE-4D82-A8FF-78442781FFE3Q49360862-42937FD4-9A86-4BB7-ADAF-8AB6922BCA40Q51223851-ED2B10EC-7456-4129-83FE-CA9898F85201Q53060401-99822BAB-9F65-40D3-B48F-7AE542EC7500Q55190386-A166C9AE-7283-4FE6-AE15-0290AB37FC0AQ88016239-E7E36F3E-4462-44CD-BBF8-FB6ECA6D9578Q90541699-0527E4EC-5477-4BA4-BD11-F48BE08F9150Q90915187-C838F50F-D4D3-4A76-A155-4626D8417D3CQ92381244-60E70F50-E818-4DF5-843C-FDD426FC4789
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Mary E Westerman
@en
Mary E Westerman
@nl
type
label
Mary E Westerman
@en
Mary E Westerman
@nl
prefLabel
Mary E Westerman
@en
Mary E Westerman
@nl
P31
P496
0000-0003-0489-5668